# A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China

> **NCT04162275** · PHASE1 · COMPLETED · sponsor: **Yiling Pharmaceutical Inc.** · enrollment: 34 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Finamine tablets
- **DRUG:** Placebo tablets

## Key facts

- **NCT ID:** NCT04162275
- **Lead sponsor:** Yiling Pharmaceutical Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-15
- **Primary completion:** 2018-04-27
- **Final completion:** 2018-04-27
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2021-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04162275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04162275, "A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04162275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*